Hikma Pharmaceuticals PLC (LON:HIK)
London · Delayed Price · Currency is GBP · Price in GBX 1,473.00
+22.00 (1.52%)
Jun 19, 2026, 8:58 AM GMT
Hikma Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 11 analysts polled by S&P Global, Hikma Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of 1,904p. The average 1-year stock price forecast is 29.24% higher than the current stock price, while the lowest is 1,355p (-8.00%) and the highest is 2,644p (+79.50%).
Price Target: 1,904p (+29.24%)
Analyst Consensus: Buy
* Price targets were last updated on May 5, 2026.
Analyst Ratings
The average analyst rating for Hikma Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 6 | 7 | 7 | 7 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 10 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Buy Reiterates 1,850p → 1,870p | Buy | Reiterates | 1,850p → 1,870p | +26.95% | May 5, 2026 |
| Berenberg Bank | Berenberg Bank | Buy Reiterates 1,800p | Buy | Reiterates | 1,800p | +22.20% | Apr 28, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains 2,000p | Buy | Maintains | 2,000p | +35.78% | Mar 3, 2026 |
| Barclays | Barclays | Sell Maintains 1,350p | Sell | Maintains | 1,350p | -8.35% | Mar 2, 2026 |
| Deutsche Bank | Deutsche Bank | Buy Reiterates 2,500p → 2,400p | Buy | Reiterates | 2,500p → 2,400p | +62.93% | Jan 9, 2026 |
Financial Forecast
Revenue This Year
3.47B
from 3.35B
Increased by 3.53%
Revenue Next Year
3.63B
from 3.47B
Increased by 4.79%
EPS This Year
2.25
from 2.26
Decreased by -0.40%
EPS Next Year
2.49
from 2.25
Increased by 10.41%
EPS and Forward PE are based on non-GAAP adjusted numbers.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 3.5B | ||
| Avg | 3.5B | ||
| Low | 3.4B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 4.7% | ||
| Avg | 3.5% | ||
| Low | 2.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 2.51 | ||
| Avg | 2.25 | ||
| Low | 1.93 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 11.0% | ||
| Avg | -0.4% | ||
| Low | -14.6% |